MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.850
-0.050 (-2.63%)
At close: Feb 21, 2025, 4:00 PM
1.810
-0.040 (-2.16%)
After-hours: Feb 21, 2025, 5:35 PM EST
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2023. The number of employees decreased by 5 or -27.78% compared to the previous year.
Employees
13
Change (1Y)
-5
Growth (1Y)
-27.78%
Revenue / Employee
n/a
Profits / Employee
-$1,995,337
Market Cap
48.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
MAIA News
- 3 days ago - MAIA Biotechnology Announces Private Placement of $2,715,000 - Business Wire
- 18 days ago - MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - MAIA Biotechnology to Present at Biotech Showcase 2025 - Business Wire
- 2 months ago - MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings - Business Wire
- 2 months ago - MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas - Business Wire
- 2 months ago - MAIA Biotechnology Announces Private Placement of Approximately $950,000 - Business Wire
- 2 months ago - MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer - Business Wire
- 3 months ago - MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - Business Wire